GIlead Sciences (GILD) stock is trading at record highs after announcing a top- and bottom-line beat for the fourth quarter ...

Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue? Over the past ...

COLUMBUS, Ohio (WCMH) — Girls at Hilltonia Middle School got a hands-on experience in health care science Tuesday. After ...

A South Korean life sciences company plans to open a genetic testing lab in North Austin, a move that could create up to 200 jobs. Last week, the Austin City Council approved a $200,000 economic ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2025 Earnings Call Transcript February 10, 2026 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $1.86, expectations were $1.81. Rebecca: ...

The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

Achieve Life Sciences is a single-asset microcap centered on cytisinicline, with an accepted NDA and a June 20, 2026, PDUFA.

The new facility will cost $137 million and will house 18 research labs, four teaching labs, a 300-seat lecture hall, and ...

They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...

Roivant saw its share prices jump by 19.4 percent week-on-week, hitting a new all-time high, as investors snapped up shares ...